NSYS

Nortech is a sub-$41M Minnesota EMS contract manufacturer (medical, imaging, aerospace/defense, industrial) in the middle of a credible operational turnaround that the market has already partly rewarded. Revenue fell 7.6% to $118M — the second straight annual decline off the FY2023 peak of $139M — driven by Aerospace & Defense collapsing 24.4% (consolidation into Bemidji, customer-approval delays) and Industrial down 12.9% on order delays and part shortages. Yet the earnings quality improved sharply where it counts: gross margin expanded 210bps to 15.2%, operating income swung to a positive $975K from a $195K loss, and operating cash flow tripled to $2.74M. The net line is essentially breakeven (-$252K), a real improvement from -$1.29M. Management's facility consolidation (closed/sold Blue Earth) and lean push are showing up in the margin, and total order backlog rose 17.4% to $77.3M with 90-day backlog up 3.2% — a genuine forward signal that the revenue slide may be nearing a floor.

On valuation the stock screens cheap on the surface — 0.3x sales and roughly 1.17x book (book equity $34.5M vs. $40.5M cap) — but that discount is the norm for a thin-margin EMS with 15% gross margins and near-zero operating margin, not a mispricing. There is real embedded earnings power: the company netted $6.87M as recently as FY2023, so a return to mid-cycle profitability would put the P/E in single digits. The problem for a buyer today is that the price has already moved: the 10-K shows NSYS traded in a $6.50–$12.40 band through all of 2025, and it now sits at $14.55 — above that entire range — meaning the trough-value entry point is gone and the -8.83% down day suggests that momentum is wobbling.